Blood stem cell collections in multiple myeloma: Definition of a scoring system

A. Corso, S. Caberlon, G. Pagnucco, C. Klersy, P. Zappasodi, E. P. Alessandrino, L. Vanelli, S. Mangiacavalli, M. Lazzarino, C. Bernasconi

Research output: Contribution to journalArticle

Abstract

The purpose of the study was to identify factors that could predict good yields of peripheral blood stem cells (PBSC) in multiple myeloma (MM). Fifty-one MM patients, nine with refractory disease and 42 in plateau phase, were mobilized with high-dose cyclophosphamide (HD-Cy) at 4 g/m2 followed by granulocyte colony-stimulating factor (G-CSF) 5 μg/kg/day. Clinical and laboratory parameters at the time of mobilization were analyzed for correlations with the number of CD34+ cells collected, with the colony-forming unit granulocyte-macrophage (CFU-GM) count, and the mononuclear cell (MNC) count. In univariate analysis, low WBC count, low platelet count, prior exposure to melphalan, and an interval > 6 months from the start of treatment correlated with poor yields of CD34+ cells. Low platelet count, prior exposure to melphalan or to radiotherapy, and an interval > 6 months from the start of treatment were associated with a low CFU-GM count. On the basis of these data, we defined a scoring system able to predict the yield of the mobilizing procedure. According to this system, the presence of more than one risk factor (low WBC and platelet counts, prior exposure to melphalan, interval from first chemotherapy > 6 months) was predictive of insufficient collections when a conventional combination of mobilizing measures are used.

Original languageEnglish
Pages (from-to)283-286
Number of pages4
JournalBone Marrow Transplantation
Volume26
Issue number3
Publication statusPublished - 2000

Fingerprint

Melphalan
Multiple Myeloma
Platelet Count
Blood Cells
Granulocyte-Macrophage Progenitor Cells
Stem Cells
Cell Count
Granulocyte Colony-Stimulating Factor
Cyclophosphamide
Radiotherapy
Drug Therapy
Therapeutics

Keywords

  • CD34 cells
  • Mobilization
  • Multiple myeloma
  • Peripheral blood stem cell

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Corso, A., Caberlon, S., Pagnucco, G., Klersy, C., Zappasodi, P., Alessandrino, E. P., ... Bernasconi, C. (2000). Blood stem cell collections in multiple myeloma: Definition of a scoring system. Bone Marrow Transplantation, 26(3), 283-286.

Blood stem cell collections in multiple myeloma : Definition of a scoring system. / Corso, A.; Caberlon, S.; Pagnucco, G.; Klersy, C.; Zappasodi, P.; Alessandrino, E. P.; Vanelli, L.; Mangiacavalli, S.; Lazzarino, M.; Bernasconi, C.

In: Bone Marrow Transplantation, Vol. 26, No. 3, 2000, p. 283-286.

Research output: Contribution to journalArticle

Corso, A, Caberlon, S, Pagnucco, G, Klersy, C, Zappasodi, P, Alessandrino, EP, Vanelli, L, Mangiacavalli, S, Lazzarino, M & Bernasconi, C 2000, 'Blood stem cell collections in multiple myeloma: Definition of a scoring system', Bone Marrow Transplantation, vol. 26, no. 3, pp. 283-286.
Corso, A. ; Caberlon, S. ; Pagnucco, G. ; Klersy, C. ; Zappasodi, P. ; Alessandrino, E. P. ; Vanelli, L. ; Mangiacavalli, S. ; Lazzarino, M. ; Bernasconi, C. / Blood stem cell collections in multiple myeloma : Definition of a scoring system. In: Bone Marrow Transplantation. 2000 ; Vol. 26, No. 3. pp. 283-286.
@article{b92dbdf2c1694381a25b5ebb676e6c05,
title = "Blood stem cell collections in multiple myeloma: Definition of a scoring system",
abstract = "The purpose of the study was to identify factors that could predict good yields of peripheral blood stem cells (PBSC) in multiple myeloma (MM). Fifty-one MM patients, nine with refractory disease and 42 in plateau phase, were mobilized with high-dose cyclophosphamide (HD-Cy) at 4 g/m2 followed by granulocyte colony-stimulating factor (G-CSF) 5 μg/kg/day. Clinical and laboratory parameters at the time of mobilization were analyzed for correlations with the number of CD34+ cells collected, with the colony-forming unit granulocyte-macrophage (CFU-GM) count, and the mononuclear cell (MNC) count. In univariate analysis, low WBC count, low platelet count, prior exposure to melphalan, and an interval > 6 months from the start of treatment correlated with poor yields of CD34+ cells. Low platelet count, prior exposure to melphalan or to radiotherapy, and an interval > 6 months from the start of treatment were associated with a low CFU-GM count. On the basis of these data, we defined a scoring system able to predict the yield of the mobilizing procedure. According to this system, the presence of more than one risk factor (low WBC and platelet counts, prior exposure to melphalan, interval from first chemotherapy > 6 months) was predictive of insufficient collections when a conventional combination of mobilizing measures are used.",
keywords = "CD34 cells, Mobilization, Multiple myeloma, Peripheral blood stem cell",
author = "A. Corso and S. Caberlon and G. Pagnucco and C. Klersy and P. Zappasodi and Alessandrino, {E. P.} and L. Vanelli and S. Mangiacavalli and M. Lazzarino and C. Bernasconi",
year = "2000",
language = "English",
volume = "26",
pages = "283--286",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Blood stem cell collections in multiple myeloma

T2 - Definition of a scoring system

AU - Corso, A.

AU - Caberlon, S.

AU - Pagnucco, G.

AU - Klersy, C.

AU - Zappasodi, P.

AU - Alessandrino, E. P.

AU - Vanelli, L.

AU - Mangiacavalli, S.

AU - Lazzarino, M.

AU - Bernasconi, C.

PY - 2000

Y1 - 2000

N2 - The purpose of the study was to identify factors that could predict good yields of peripheral blood stem cells (PBSC) in multiple myeloma (MM). Fifty-one MM patients, nine with refractory disease and 42 in plateau phase, were mobilized with high-dose cyclophosphamide (HD-Cy) at 4 g/m2 followed by granulocyte colony-stimulating factor (G-CSF) 5 μg/kg/day. Clinical and laboratory parameters at the time of mobilization were analyzed for correlations with the number of CD34+ cells collected, with the colony-forming unit granulocyte-macrophage (CFU-GM) count, and the mononuclear cell (MNC) count. In univariate analysis, low WBC count, low platelet count, prior exposure to melphalan, and an interval > 6 months from the start of treatment correlated with poor yields of CD34+ cells. Low platelet count, prior exposure to melphalan or to radiotherapy, and an interval > 6 months from the start of treatment were associated with a low CFU-GM count. On the basis of these data, we defined a scoring system able to predict the yield of the mobilizing procedure. According to this system, the presence of more than one risk factor (low WBC and platelet counts, prior exposure to melphalan, interval from first chemotherapy > 6 months) was predictive of insufficient collections when a conventional combination of mobilizing measures are used.

AB - The purpose of the study was to identify factors that could predict good yields of peripheral blood stem cells (PBSC) in multiple myeloma (MM). Fifty-one MM patients, nine with refractory disease and 42 in plateau phase, were mobilized with high-dose cyclophosphamide (HD-Cy) at 4 g/m2 followed by granulocyte colony-stimulating factor (G-CSF) 5 μg/kg/day. Clinical and laboratory parameters at the time of mobilization were analyzed for correlations with the number of CD34+ cells collected, with the colony-forming unit granulocyte-macrophage (CFU-GM) count, and the mononuclear cell (MNC) count. In univariate analysis, low WBC count, low platelet count, prior exposure to melphalan, and an interval > 6 months from the start of treatment correlated with poor yields of CD34+ cells. Low platelet count, prior exposure to melphalan or to radiotherapy, and an interval > 6 months from the start of treatment were associated with a low CFU-GM count. On the basis of these data, we defined a scoring system able to predict the yield of the mobilizing procedure. According to this system, the presence of more than one risk factor (low WBC and platelet counts, prior exposure to melphalan, interval from first chemotherapy > 6 months) was predictive of insufficient collections when a conventional combination of mobilizing measures are used.

KW - CD34 cells

KW - Mobilization

KW - Multiple myeloma

KW - Peripheral blood stem cell

UR - http://www.scopus.com/inward/record.url?scp=0033855585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033855585&partnerID=8YFLogxK

M3 - Article

C2 - 10967566

AN - SCOPUS:0033855585

VL - 26

SP - 283

EP - 286

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -